Synaffix BV, of Amsterdam, said preclinical studies showed that its platform technologies, Glycoconnect and Hydraspace, generated antibody drug conjugates (ADCs) with improved therapeutic index in comparison to the ADCs Kadcyla (trastuzumab emtansine, Genentech Inc./Roche Group) and Adcetris (brentuximab vedotin, Seattle Genetics Inc.), approved by the FDA to treat HER2-positive breast cancer and multiple lymphoma indications, respectively.